OTLK - EFECTIVE NOV 01, 2026 - Blue Cross Blue Shield of NORTH DAKOTA includes LYTENAVA
Retina Consultants of America (RCA), which is owned by Cencora, has an active presence and serves patients in North Dakota.
Blue Cross Blue Shield of North Dakota (BCBSND) has added Lytenava (bevacizumab-vikg) to its new Commercial prior authorization medical drug policies, effective November 1, 2026.
Key Details
- Drug Name: Lytenava (bevacizumab-vikg).
- Effective Date: November 1, 2026.
- Policy Type: Commercial prior authorization medical drug policy.
- Indication: Ophthalmic formulation approved for neovascular (wet) age-related macular degeneration (nAMD).
- Contact Support: Provider Service is available at 800-368-2312, and Medicaid Expansion inquiries can reach 833-777-5779. Further policy display information can be checked directly via BCBSND Pharmacy Policies.
According to an official bulletin published on the BCBSND Healthcare News Portal, Blue Cross Blue Shield of North Dakota has formally designated Lytenava (bevacizumab-vikg) under its new Commercial prior authorization medical drug policies.
The policy update is explicitly scheduled to become effective on November 1, 2026. Providers can look up the complete clinical criteria on the insurer's policy portal on or after that effective date.